Thursday, June 27, 2013
Aragon Pharmaceuticals Inc.
researchers have uncovered how a specific androgen
receptor mutation results in turning second-generation
antagonists for prostate cancer into agonists.1 The results could
allow the company, which is being acquired by Johnson & Johnson, to
develop third-generation molecules that overcome the resistance mechanism.
is a charm
Donner, A. SciBX 6(25); doi:10.1038/scibx.2013.615 Published online June
1. Joseph, J.D. et al.
Cancer Discov.; published online June 18, 2013; doi:10.1158/2159-8290.CD-13-0226
Contact: Jeffrey H. Hager, Aragon Pharmaceuticals Inc., San Diego,
Calif. e-mail: firstname.lastname@example.org
Contact: James D. Joseph, same affiliation as above e-mail: email@example.com
2. Taplin, M.-E. Nat.
Clin. Pract. Oncol. 4, 236-244 (2007)
3. Balbas, M.D. et al.
eLife 2, e00499; published online April 9, 2013;
4. Lou, K.-J. SciBX
Aragon Pharmaceuticals Inc., San Diego, Calif.
Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif.
Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Toyota Technological Institute at Chicago, Chicago, Ill.
The University of Chicago, Chicago, Ill.